AGENDA

Head of Section: Data Integration and Analysis; Division of Infection preparedness; Statens Serum Institut.

Education: MD, Ph.D, consultant and specialist in clinical microbiology

Marianne has spent day and night during the epidemic to organize the integration and use of lab- and register data, and furthermore been involved in the development of new digital solutions. She has furthermore been involved in Statens Serum Institut’s role as government advisor.

M Voldstedlund has a special interest in bridging the gaps between Clinical Microbiology, Public Health medicine and IT-technology. M Voldstedlund is responsible for developing a national digital surveillance system for infectious diseases.

Angelika Rzepka is a Scientist at the AIT – Austrian Institute of Technology GmbH. She holds a master degree in Health Care Engineering and a second master degree in Public Health. She is responsible for coordinating projects in the business unit Digital Health Information Systems and writes competitive proposals for public funding. She mainly concentrates on integrated care networks and according care paths, as well as accessibility for TeleHealth solutions in Austria’s public health system.

CEO and Co-founder for Lybe Scientific. I have a background as MSc in Biotechnology and PhD in Medical Technology. Worked with cancer research at NTNU and MIT before I started to work as a Business Developer at NTNU Technology Transfer focusing on medical technology and life science ideas.

Freimut Schliess heads Science & Innovation at Profil GmbH (www.profil.com) – a CRO for early phase clinical trials in diabetes, NAFLD and cardiovascar disease. Freimut is leading the CLOSE and RealWorld4Clinic EIT Health innovation initiatives. In iPDM-GO he contributes to exploring the usage of epidemiological data and artificial intelligence tools for adapting diabetes management to the requirements of Value Based Healthcare. One of his ambitions is to close the gap between the outcomes of well controled clinical trials and the effectiveness of treatments in real world healthcare.

Sr Medical Advisor Cardiovascular, kAmgen and initiator of FHabian.

Founder, Chief Executive Officer, Intensive Care Specialist

• Study of medicine in Aachen, MBA in Nürnberg
• Senior physician at the clinic for Operative Intensive Care and Intermediate Care (Uniklinik RWTH Aachen)
• Habilitation and Venia legendi for anaesthesiology and intensive care
• Senior Lecturer for Business in Translational Medicine at the Queen Mary University London
• Leader of the task force “Artificial Intelligence Lab (AI4CC)” of the Uniklinik RWTH Aachen

Karl H. Peterson is the member of management board of the Estonian Health Insurance Fund who is responsible for digitalization and change within the organization and across the Estonian healthcare sector.

He has held multitude of different roles throughout his 25-year career covering most IT related areas from specialist to top management in financial institutions. He has held key roles during four different global crises learning how to turn a crisis into an advantage.

Karl has experience in rapid changes involving large projects over multiple culture spaces and countries and can attest to Nassim Nicholas Talebs wise words „History and societies do not crawl. They make jumps. They go from fracture to fracture, with a few vibrations in between.“

Co-founder of Health Tech Hub Copenhagen, driving up the scaling and adoption of clever, responsible health tech.

Former Head of Innovation at Momentum Mental Healthcare (Netherlands). Worked on prevention models and expanding care outside of the clinics. As top-tier management consultant, helped health and tech clients on four continents. Digital Vanguard for Exponential Medicine.

A physicist by training, with a PhD in Molecular Biophysics from Karolinska Institutet and a career at Government Agencies such as Vinnova and the Ministry of Enterprise and Innovation, Anna Sandström is today Science Policy and Relations Director for Europe at AstraZeneca, with focus on Sweden, United Kingdom and EU. She is elected member of the Royal Swedish Academy of Engineering Sciences and is board member of the Royal Institute of Technology and the synchrotron light source MaxIV as well as EIT Health Scandinavia and heads the R&D committee of the trade body SwedenBIO.